objective responses (ORR)

mCRC - 1st line (L1) metastatic/advanced - colorectal cancer (mCRC) mCRC - 1st line (L1)

versus Bevacizumab plus FOLFOXIRI
atezolizumab plus FOLFOXIRI plus bevacizumab vs. Bevacizumab plus FOLFOXIRI 1 certainty unassessable-20%